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 ABSTRACT
 Cancer cells efﬁ ciently transfer exosome contents (essentially mRNAs and 
microRNAs) to other cell types, modifying immune responses, cell growth, angiogenesis 
and metastasis. Here we analyzed the exosomes release by breast tumor cells with 
different capacities of stemness/metastasis based on CXCR4 expression, and evaluated 
their capacity to generate oncogenic features in recipient cells. Breast cancer cells 
overexpressing CXCR4 showed an increase in stemness-related markers, and in 
proliferation, migration and invasion capacities. Furthermore, recipient cells treated 
with exosomes from CXCR4-cells showed increased in the same abilities. Moreover, 
inoculation of CXCR4-cell-derived exosomes in immunocompromised mice stimulated 
primary tumor growth and metastatic potential. Comparison of nucleic acids contained 
into exosomes isolated from patients revealed a “stemness and metastatic” signature 
in exosomes of patients with worse prognosis. Finally, our data supported the view 
that cancer cells with stem-like properties show concomitant metastatic behavior, and 
their exosomes stimulate tumor progression and metastasis. Exosomes-derived nucleic 
acids from plasma of breast cancer patients are suitable markers in the prognosis of 
such patients. 
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 INTRODUCTION 
 Exosomes are a type of nanovesicles that differ 
from other extracellular vesicles in their endocytic origin, 
their size (40–100 nm) and their speciﬁ c molecular 
cargo. Exosomes released from cells, including tumor 
cells, provide a signiﬁ cant mechanism of intercellular 
communication. Previous studies in cancer cells have 
shown that these released nanovesicles transfer their 
content to other cell types, modifying immune responses, 
cell growth, angiogenesis and metastasis [ 1 , 2 ]. 
 Breast cancer is the most commonly diagnosed 
cancer in women [ 3 ], and metastasis is responsible for 
morbidity and the majority of cancer-related death. 
Metastasis is a multi-step evolutionary process in which 
cancer cells acquire alterations allowing them to transcend 
their programmed behavior to disseminate from the 
primary tumor, intravasate into the blood circulation and 
eventually extravasate into foreign tissues. Ultimately, 
a few of these cells (0.01–0.02%) will adapt to the new 
distal microenvironment and form macrometastases [ 4 ]. 
Moreover, only a subpopulation of cancer cells with 
stem-like properties is competent to initiate tumor growth 
and disseminate to distant organs [ 5 , 6 ]. These cancer 
stem cells (CSC) are able to self-renew and generate the 
heterogeneous lineages of cancer cells that comprise the 
tumor. Furthermore, these cells have phenotypic plasticity 
and resist drug-induced DNA damage. Collectively, the 
capacity of these cells to evade destruction and survive 
at distal sites makes CSC more likely to support the 
establishment of primary tumors and to succeed in the 
later steps of metastasis. In addition, this property may 
explain why micrometastases can remain dormant after 
removal of the primary tumor and recur many years later 
[ 7 , 8 ]. Thus, these CSCs are responsible for metastatic 
growth in breast cancer which contributes to majority of 
the breast cancer related morbidity and mortality. 
 Recently, many studies have shown that the 
presence of the chemokine receptor CXCR4 is involved in 
many stages of tumorigenesis, as invasion and metastasis 
in several cancers, including breast cancer [ 9 ]. The 
paracrine and endocrine effects through CXCL12/CXCR4 
are critical for tumor growth, invasion, angiogenesis and 
metastasis [ 10 ]. This axis is also involved in cancer stem 
cell characteristics [ 11 , 12 ], and is an important marker for 
metastatic potential of CSC [ 13 ]. Furthermore, increased 
CXCR4 is correlated with high risk for recurrence and 
poor overall survival in multiple cancer patients including 
breast, lung, kidney, colon, ovarian, and brain cancers, as 
well as lymphoma and leukemia. 
 There is therefore a need to better understand 
mechanisms associated with metastatic process in breast 
cancer. We used a model based on CXCR4-transfected 
culture to analyze the role of exosomes released from 
breast tumor cells with different stemness/metastasis 
abilities in the capacities for tumor growth, generation 
of stem cell features in neighboring cells, and metastatic 
potential. Finally, exosomes from plasma of breast cancer 
patients were characterized and assessed their capacity as 
prognostic marker in liquid biopsy. 
 RESULTS 
 For this study, we used the expression of aldehyde 
dehydrogenase (ALDH) to identify cancer cells with 
stem cell features in three human breast cancer cell lines. 
Similarly, as described elsewhere [ 14 ], HCC38 cell line 
showed 100% of ALDH-positive cells, whereas MDA-
MB-231 and T47D cell lines showed 1% and 0% of 
ALDH-positive cells respectively (Supplementary Figure 
S1A). Therefore, T47D cells showed absence of stem cell 
features, and previously, it has been broadly identiﬁ ed as 
non-invasive and non-metastasic, forming tumors only 
in the presence of oestrogen [ 15 ]. For these reasons, this 
cell line was selected to stably transfect CXCR4 gene 
(Supplementary Figure S1B) and to study the paracrine 
effect of its exosomes when CXCR4 is overexpressed. 
HCC38 and MDA-MB-231 cell lines were used as controls 
of stemness and metastatic capacities, respectively. 
 Before of analyse the potential effects of exosomes 
released by CXCR4-cells, we tested the effects of 
CXCR4 overexpression in the transfected breast cancer 
cell line. As expected, CXCR4 expression increases 
proliferation, migration and invasion capabilities 
 in vitro (Supplementary Figure S2A–S2C). Moreover, 
contribution of CXCR4 to tumorigenic and metastatic 
capacities was observed in two  in vivo models: using a 
tumorogenic/metastatic cell line (MDA-MB-231) and a 
non-tumorogenic cell line (T47D) (Supplementary Figure 
S2D–S2G). Moreover, CXCR4-cells showed increased 
expression of stemness-related markers (Supplementary 
Figure S3). Together, these results using  in vitro and 
 in vivo models indicate that expression of CXCR4 
stimulates tumorogenic and metastatic capacities in breast 
cancer cells, conﬁ rming previously described data. 
 Exosomes released by CXCR4-cells increase, by 
a paracrine manner, stemness-related markers 
expression, proliferation, migration and invasion 
 in vitro in breast cancer cells 
 Correct exosomes isolation were conﬁ rmed by 
transmission electron microscopy (Supplementary Figure 
S4A) and nanoparticle tracking analysis (Supplementary 
Figure S4B), which revealed vesicles within the expected 
size range (50–100 nm). Moreover, immunoblotting 
conﬁ rmed the presence of exosomal proteins CD63 and 
CD81 and the absence of negative control Calnexin 
(Supplementary Figure S4C). To analyze the uptake of 
exosomes by recipient cells, T47D-CXCR4 exosomes 
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were labelled with PKH67 dye and added them to cultures 
of T47D cells. Confocal microscopy conﬁ rmed the 
internalization of T47D-CXCR4 exosomes in T47D cells 
(Supplementary Figure S4D). 
 Expression of genes involved in stemness was 
quantiﬁ ed in T47D recipient cells after addition of 
T47D-CXCR4 exosomes. As the epithelial-mesenchymal 
transition (EMT) has been implicated in the generation of 
stem cell properties [ 16 ], expression of  SNAI1 and  CDH1 
was also quantiﬁ ed. We found increased expression of 
stemness- and EMT-related mRNAs in T47D cells after 
addition of T47D- and MDA-MB-231-CXCR4 exosomes 
(Figure  1A ). 
 After addition of exosomes from T47D-CXCR4 
cells, T47D cells exhibited higher proliferation capacity 
than T47D cells incubated with equal amount of exosomes 
from T47D mock cells. Similarly, T47D cells incubated 
with MDA-MB-231- and HCC38-exosomes showed 
increased proliferation with respect to control cells 
(Figure  1B ). T47D cells incubated with exosomes from 
 Figure 1:  A. mRNA expression of stemness-related markers in recipient cells after addition of exosomes released by CXCR4-
transfected cells. B. Proliferation assay, C. migration assay and D. invasion assay in recipient cells after addition of exosomes released by 
CXCR4-transfected cells, HCC38 and MDA-MB-231 cells. *p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.005. 
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T47D-CXCR4 and MDA-MB-231 showed increased 
migration potential with respect to T47D cells incubated 
with T47D-mock exosomes (Figure  1C ). In contrast, T47D 
cells incubated with exosomes from HCC38 cells showed 
lower migration capacity. Similarly, T47D cells incubated 
with exosomes from T47D-CXCR4 showed increased 
invasion with respect to cells incubated with T47D-mock 
exosomes. T47D cells incubated with exosomes from 
HCC38 cells showed lower invasion capacity (Figure  1D ). 
 These results indicate that exosomes derived from 
CXCR4-tumor cells modify stemness markers, proliferation, 
migration and invasion features of neighbouring cells. 
 Exosomes released by CXCR4-cells increase the 
oncogenic potential of tumor cells in mice 
 Next, roles of CXCR4-cells-derived exosomes 
in primary tumor growth and metastatic capacity 
were examined in two animal models: a tumorogenic/
metastatic model using MDA-MB-231 cell line, and a 
non-tumorogenic model using T47D cell line. 
 In the ﬁ rst model, ten mice were treated with MDA-
MB-231-CXCR4- or mock-exosomes intravenously 
injected, starting one day after orthotopic injection of 
MDA-MB-231 FLuc cells. Cells with ﬁ reﬂ y luciferase (F Luc ) 
reporter gene were used to improve the evaluation of 
metastasis. In mice injected with MDA-MB-231-CXCR4 
exosomes, primary tumors showed enhanced tumor 
growth (Figure  2A ), high percentage of Ki67 positive 
cells (Figure  2B ) and increased levels of stemness/EMT-
related mRNAs (Figure  2C ). In addition, more metastasis 
was detected by  ex vivo Bioluminescent Imaging (BLI) in 
mice treated with CXCR4-exosomes (Figure  3A ): lymph 
nodes (ten mice), lung (three mice) and brain (one mouse) 
(Figure  3B ). With mock-exosomes treatment, metastasis 
was only detected in lymph nodes of nine mice. Metastatic 
lesions were conﬁ rmed by immunohistochemistry using 
haematoxylin and eosin stain (Figure  3C ). 
 Other mouse model was performed based on non-
tumorogenic/metastatic cell line (T47D). Interestingly, 
mice treated with T47D-CXCR4 exosomes showed lymph 
node micrometastasis (Supplementary Figure S5). 
 These data indicate that exosome cargo from 
CXCR4-cells enhance tumor growth and metastatic 
potential in breast cancer models. 
 Exosomes released by T47D-CXCR4 are 
enriched in mRNAs related with stemness and 
metastasis 
 Trying to identify the possible mediators involved in 
the cross-talk between different cells through exosomes, 
the genetic information contained in exosomes released by 
T47D-CXCR4 cells was analyzed by PCR arrays. Thus, 
PCR arrays with most representative mRNAs involved in 
metastasis and stem cell differentiation and development 
were performed in T47D-CXCR4 exosomes  versus 
T47D-mock exosomes and HCC38 exosomes. T47D-
CXCR4 exosomes were highly enriched in genes related 
with stem cell differentiation and development. Similarly, 
exosomes isolated from HCC38 cells (100% ALDH-
positive) were highly enriched in these types of mRNA 
(Supplementary Figure S6). Thus, CXCR4 expression is 
involved in exosomes-gene expression proﬁ le changes 
related to biological process enrichment found in tumor 
cells with high stemness potential. The top ten enriched 
mRNAs carried in exosomes are shown in Supplementary 
Table S1. 
 Stemness and metastasis-related mRNAs 
contained in exosomes from plasma patients with 
breast cancer are associated with poor prognosis 
 In the same way, mRNAs related with stemness 
and metastasis were compared in pools of exosomes from 
plasma of patients by PCR array analysis. Patients were 
divided in two pools in base of their outcome: “Good 
outcome” and “Poor outcome” pool. Good outcome 
pool included patients without ﬁ rst relapse and death, 
and large follow-up (median follow-up of 119 months). 
Poor outcome pool included patients with ﬁ rst relapse and 
death, and short survival (median follow-up of 17 months). 
Levels of 8 metastasis-related mRNAs and 27 stemness-
related mRNAs were higher in exosomes from patients 
with poor prognosis than in exosomes from patients with 
good prognosis. Supplementary Figure S6 shows the 
number of mRNAs with high levels detected in T47D-
CXCR4 and HCC38 cells, and in the pool of patients with 
poor prognosis. mRNAs with highest levels detected in 
exosomes of poor prognosis pool ( NANOG ,  NEUROD1 , 
 HTR7 ,  KISS1R ,  HOXC6 ) were also increased in exosomes 
released by T47D-CXCR4 and HCC38 (Supplementary 
Table S1). These mRNAs were analyzed by real-time PCR 
in a large series of plasma from 173 breast cancer patients. 
 The patient series was followed for a mean of 73 
months (range: 1–136). Individual survival analysis 
of each selected mRNA showed associations between 
high mRNA levels and patients DFS or OS (Figure  4 
and Supplementary Table S2A). When levels of mRNA 
in exosomes from plasma were stratiﬁ ed for hormone 
receptors and HER2, associations were found between 
poor outcome in patients and high mRNA levels in 
exosomes in hormone-positive receptors and HER2-
negative subgroups (Supplementary Figure S7 and 
Supplementary Table S2B–S2C). Moreover, high  NANOG 
mRNA levels were associated with short DFS in the 
HER2-positive subgroup. 
 To study the possible additive effect of the selected 
mRNAs as a “stemness and metastatic signature”, the 
patients were grouped according to the number of 
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 Figure 2:  A. Evolution of tumor growth in immunodeﬁ cient mice intravenously injected with MDA-MB-231-CXCR4-derived 
exosomes.  In vivo ventral coelenterazine-based F Luc -BLI images of a representative mouse (* p ≤ 0.05).  B. Ki67 immunohistochemistry 
of primary tumors developed in immunodeﬁ cient mice intravenously injected with MDA-MB-231-CXCR4-derived exosomes (*** p ≤ 
0.005).  C.  CXCR4 ,  NANOG and  SNAI1 mRNA levels in primary tumors developed in immunodeﬁ cient mice intravenously injected with 
MDA-MB-231-CXCR4-derived exosomes as compared with tumors in mice treated with MDA-MB-231-mock-derived exosomes (* p ≤ 
0.05; and *** p ≤ 0.005). 
Oncotarget40580www.impactjournals.com/oncotarget
 Figure 3:  Metastasis after fat pad injection of MDA-MB-231 FLuc cells in mice treated with exosomes.  A.  Ex vivo D-luciferin-
based F Luc -BLI images of excised lung, brain, lymph nodes and spleen of a representative mouse.  B. Quantiﬁ cation of total photon ﬂ ux in 
lymph nodes (* p ≤ 0.05).  C. Hematoxylin and eosin-stained sections taken from different part of lymph nodes and lungs (10X and 20X 
images are shown). 
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mRNA with high levels in plasma exosomes. Thus, 
patients were ﬁ rst classiﬁ ed on the basis of high levels 
of zero, one, two, three, four or ﬁ ve mRNAs. A clear 
association was observed between increased exosome-
derived nucleic acids and breast cancer patients DFS 
or OS ( P = 0.021 and  P = 0.016, respectively). Next, 
to dichotomize the analysis, and based on similar 
mathematical behavior, patients with high levels of 
zero, one or two mRNAs were grouped as “low-levels” 
and those with more than three mRNAs were grouped 
as “high-levels”. Interestingly, correlation between 
DFS or OS previously observed was stronger (Figure 
 5A and Supplementary Table S3). Adjusted analysis 
showed that this “stemness and metastatic signature” 
in exosomes had an independent relationship with OS 
and a trend with DFS (Table  1 ). In hormone receptor-
positive and HER2-negative breast cancers, high levels 
of this signature were signiﬁ cantly associated with 
shorter DFS and OS (Figure  5B – 5C and Supplementary 
Table S3). Moreover, relationships were found between 
clinicopathological parameters and signature high levels 
in exosomes (Supplementary Table S4). 
 Figure 4:  A. Kaplan-Meier DFS curves in relation to levels of validated mRNA in exosomes from total series patients.  B. Kaplan-Meier 
OS curves in relation to levels of validated mRNA in exosomes from total series patients. 
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 Figure 5:  Kaplan-Meier DFS and OS curves in relation to “stemness and metastatic signature” levels in exosomes  from A. total 
series patients, and patients classiﬁ ed on the basis of  B. hormone receptors and  C. HER2 status. 
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 Together, these results support the involvement of 
“stemness and metastatic” signature in exosome-derived 
nucleic acids in breast cancer patient survival. 
 DISCUSSION 
 In summary, this study demonstrates how exosomes 
derived from CXCR4-breast tumor cells modify stemness 
markers and enhance proliferation, migration and invasion 
abilities of neighboring cells. The  in vivo signiﬁ cance 
of these ﬁ ndings is documented by the observation 
that inoculation of CXCR4-cells-derived exosomes in 
immunocompromised mice enhanced primary tumor 
growth and metastatic potential. Furthermore, clinical 
relevance is indicated by the observation that comparative 
analysis of mRNAs contained in exosomes isolated from 
patients revealed a gene signature of nucleic acids highly 
enriched in exosomes of patients with worse prognosis. 
 Exosomes inﬂ uence most tumor-related pathways, 
such as proliferation, angiogenesis, EMT, promotion of 
immune escape, cancer stemness and metastasis involving 
many cell types within the tumor microenvironment [ 2 , 17 ]. 
Regarding the stemness and the dissemination potential, 
cancer stem cell and metastatic cells share comparable 
behaviour and properties such as the capacity for self-
renewal, the requirement for a speciﬁ c microenvironment 
to grow and the SDF1/CXCR4 axis [ 18 ]. In line with the 
proposal that CSC shape the disseminating subpopulation of 
tumor cells, the positive correlation between EMT and CSC 
properties supports the theory of “migrating cancer stem 
cells” as the basis of metastasis colonization [ 19 ]. Numerous 
studies have reported that CSC also express EMT-related 
markers, and more crucially, that induction of EMT promotes 
the generation of CSC in transformed epithelial cells [ 18 , 20 ]. 
Our study focused on these parallel characteristics in several 
culture models, based on the transfection of CXCR4, a 
widely accepted chemokine receptor implicated in metastasis 
of breast cancer cells that also is overexpressed in breast 
cancer stem cells (CSC) [ 21 , 22 ]. The main goal of the study 
is the contribution of exosomes released from CXCR4-breast 
tumor cells to tumor growth, dissemination capacity and 
generation of stem cell features after uptake by recipient cells. 
 In concordance with roles of CXCR4 described 
above, CXCR4-cells showed well known EMT-related 
features, elevated expression of several stem cell-related 
genes and surface markers, and higher proliferation rates, 
migration activity and cell invasiveness than mock cells. 
These results are in line with others studies performed 
in breast cancer cell lines transfected with CXCR4 [ 23 ]. 
Interestingly, our data indicate that this observation was 
supported by analysing the contribution of CXCR4-cell-
derived exosomes to tumorigenic capacity in acceptor cells. 
Collectively, the  in vitro set of developed experiments 
showed that CXCR4-cells-derived exosomes entailed 
an increase in stemness- and EMT-related markers and 
induced proliferation, migration and invasion capacities in 
non-pluripotent/non-invasive recipient cells. 
 CXCR4 overexpression promoted metastatic 
potential and oestrogen independence tumor growth  in 
vivo , similarly to previous studies performed in MCF7 
cells. Thus, tumor stem-like cells show metastatic 
behaviour [ 5 , 6 ]. Accordingly, our  in vivo experiments in 
immunocompromised mice inoculated with CXCR4-cell-
derived exosomes established that exosomes increased 
primary tumor growth and metastatic potential. Together, 
these ﬁ ndings indicate that exosomes released by cancer 
cells with parallel stem-like and metastatic properties 
transfer these oncogenic features to recipient cells. 
 Our study identiﬁ ed a speciﬁ c T47D-CXCR4-derived 
exosome signature highly enriched in nucleic acids related to 
both stem cell differentiation and metastasis. Interestingly, this 
signature was highly homologous to the content of exosomes 
 Table 1:  Multivariate cox analysis of the association between “stemness and metastatic signature” 
and DFS and OS of breast cancer patients 
  Variable  Category  Adjusted Analysis  P Value 
    Hazard Ratio  95% CI 
 DFS  PR  Positive  vs Negative  0.28  0.11–0.74  0.010 
  HER2  Positive  vs Negative  3.53  1.2–10.2  0.020 
  RT  progression  vs complete  23.13  5.05–106.08  <0.001 
  Signature level  High  vs Low  2.68  0.95–7.53  0.062 
 OS  VLI  Yes  vs No  5.52  2.03–15.04  0.001 
  HR  Positive  vs Negative  0.16  0.06–0.42  <0.001 
  RT  progression  vs complete  18.15  2.04–161.65  0.009 
  Signature level  High  vs Low  5.77  2.23–14.95  <0.001 
 VLI, vascular and lymphatic invasion; PR, progesterone receptor; HR, hormone receptors; RT: response to treatment. 
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derived from HCC38, a cell line strongly positive for markers 
related with breast cancer stem cell subpopulations. 
 Moreover, by comparing the nucleic acids into 
exosomes from plasma of breast cancer patients divided by 
poor and good prognostic, several stemness and metastatic-
related mRNAs in exosomes were identiﬁ ed, which were 
also increased in CXCR4-exosomes. Thus, we observed 
that levels of these mRNAs in exosomes are related to poor 
DFS and OS. When “stemness and metastatic” signature is 
taken into consideration, this relationship is more robust. 
Moreover, multivariate analysis clearly demonstrates that 
this variable is an independent prognostic marker for breast 
cancer patients. The selected exosome-derived nucleic 
acids have been implicated in growth and proliferation, 
induced pluripotent and embryonic stem cells, somatic 
stem cell maintenance, embryonic development, symmetry 
and segmentation, and in organ morphogenesis (Kyoto 
Encyclopedia of Genes and Genomes (KEGG) v58.1). 
The clinical relevance of these ﬁ ndings is established by 
the deﬁ nition of a “stemness and metastatic signature” in 
exosomes, which showed a remarkable prognostic value 
for the clinical outcome of breast cancer patients. This 
ﬁ nding could help predict the clinical outcome and inform 
decisions about treatment, mainly in hormone receptor-
positive or HER2-negative breast cancer subgroups. 
 Here we propose that the communication through 
exosomes between cancer and surrounding cells stimulate 
tumor progression and metastasis, particularly when 
exosomes are released by breast cancer cells with stemness 
and metastatic properties. Our study reveals that CXCR4-
exosomes promote breast cancer cells proliferation, motility 
and metastasis, generating an enhanced tumorigenesis 
phenotype. Furthermore, our ﬁ ndings contribute to the 
identiﬁ cation of a breast cancer prognostic signature, 
which could be easily translated into clinical practice since 
these markers are obtained by a non-invasive method. This 
signature could also be used during patients’ follow-up to 
identify patients with worse prognosis. This data exemplify 
the ongoing efforts to understand the involvement of 
stemness and metastatic-related nucleic acids contents in 
exosomes in cancer progression. Search for new speciﬁ c 
therapies against these exosomes would offer a synergistic 
effect with current therapies in those patients usually with 
worse outcome. In this way, CXCR4-related stemness 
properties displayed by tumor cells with metastatic capacity 
could be potentially exploited for therapeutic targeting 
of CSC using treatment anti-CXCR4 (e.g. TN14003 or 
AMD3100), also avoiding the effects of their exosomes. 
 MATERIALS AND METHODS 
 Cell culture 
 Cell lines were obtained from American Type 
Culture Collection. For culture conditions details, see 
Supplementary Material. 
 T47D and MDA-MB-231 cells were stably 
transfected with Precision LentiORF expression vectors 
encoding CXCR4 or RFP control particles (Thermo 
Scientiﬁ c), using Lipofectamine 2000 (Invitrogen). One 
week post-transfection, CXCR4 and RFP-mock expressing 
cells were selected by sorter and expanded in RPMI 
supplemented with 20% FBS. MDA-MB-231 FLuc cells [ 24 ] 
were kindly provided by Dr. L. Vallina (University Hospital 
Puerta de Hierro Research Institute, Madrid, Spain). 
 Exosome isolation, identiﬁ cation and 
quantiﬁ cation 
 Cell lines were cultured in media supplemented 
with exosome-depleted FBS. FBS was depleted of 
bovine exosomes by passage through a 0.22-μm PVDF 
ﬁ lter (Millipore) and ultracentrifugation at 120,000  g
for 90 minutes. Exosomes were isolated from cell 
supernatants by a series of centrifugation and ﬁ ltration 
steps (see Supplementary Material). The exosome pellet 
was resuspended in 200 μL of phosphate-buffered saline 
(PBS) or medium with 1% exosome-depleted FBS. 
Circulating exosomes were isolated from human plasma 
with ExoQuick™ plus Thromboplastin D Kit (System 
Bioscience), in line with the manufacturer’s instructions. 
 For identiﬁ cation by transmission electron microscopy 
(model JEOL Jem1010, 100 kV) exosomes were ﬁ xed in 
2% PFA (w/v) in 200 mM phosphate buffer (pH 7.4). Fixed 
exosomes were dropped onto a formvar-carbon-coated 
grid and left to dry at room temperature for 20 minutes. 
After washing in PBS, the exosomes were ﬁ xed in 1% 
glutaraldehyde for 5 minutes, washed in water and stained 
with saturated aqueous uranyl oxalate for 5 minutes. Samples 
were then embedded in 0.4% (w/v) uranyl acetate and 1.8% 
(w/v) methylcellulose and incubated on ice for 10 minutes. 
The excess liquid was then removed. The grid was dried at 
room temperature for 10 minutes and viewed at 80,000 and 
120,000 magniﬁ cation. 
 LM10 nanoparticle characterization system 
(NanoSight) was used for real-time characterization and 
quantiﬁ cation of the vesicles in supernatant fractions and 
in samples from patients. 
 Exosome labeling 
 For the exosome-tracking experiments, puriﬁ ed 
exosomes from cell lines were ﬂ uorescently labeled using 
PKH67 membrane dye (Sigma-Aldrich) following the 
manufacturer’s instructions. Images were collected with a 
TCS SP5 confocal microscope (Leica Microsystems). For 
details, see Supplementary Information. 
 Protein extraction and western blot analysis 
 Exosomes were lysed with T-PER Tissue Protein 
Extraction buffer (Thermo Scientiﬁ c) containing a protease 
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and phosphatase inhibitor cocktail (Thermo Scientiﬁ c). 
Western Blots for CD63 (ab59479, Abcam), CD81 
(349502, BioLegend Inc.) and Calnexin (endoplasmic 
reticulum protein) as loading control (sc-11397, Santa 
Cruz Biotechnology) were performed. For details, see 
Supplementary Information. 
 RNA extraction, retrotranscription and mRNA 
quantitative analysis 
 Total RNA was extracted from cells and exosomes 
by the  mir Vana™ miRNA Isolation Kit (Ambion Inc.). 
Retrotranscription and ampliﬁ cation were performed 
using Transcription ﬁ rst-strand cDNA Synthesis Kit 
and LightCycler 480 SYBR Green I Master Kit in a 
Light-Cycler apparatus (Roche Diagnostics). For PCR 
Arrays analysis we used RT 2 PreAMP CDNA Synthesis 
Kit and RT 2 PreAMP Pathway Primer Mix for Stem 
Cell Transcription Factors and for Human Tumor 
Metastasis, in the appropriate PCR Arrays following the 
manufacturer’s instructions (Qiagen). In the validation set, 
retrotranscription was achieved as described above. Next, 
we performed a speciﬁ c pre-ampliﬁ cation using Real-
Time Ready cDNA PreAMP Master using PreAMP Primer 
Pools, followed by Real-Time Ready Custom Panels in a 
Light-Cycler apparatus (Roche Diagnostics) in line with 
the manufacturer’s instructions. 
 cDNAs were quantiﬁ ed by NanoDrop ND-1000 
(Thermo Scientiﬁ c); and concentrations were equalized to 
100 μg/μL to standardize per cDNA amount. 
 The sequences of the primer sets and the reaction 
conditions are shown in Supplementary Table S5. 
 Proliferation assay 
 Proliferation assay was performed by seeding 
cell lines (20,000 cells/well) in 96-well E-plates in 
RPMI containing 1% exosome-depleted FBS for 24 and 
48 hours. Similarly, T47D mock cells were incubated 
for 24 and 48 hours with CXCR4 or mock breast tumor-
derived exosomes, and viable cells were detected using 
the MTT Cell Proliferation Assay Kit (Cayman Chemical 
Company). Absorbance was measured on a microplate 
reader at 570 nm (Multiskan Ex; Thermo Scientiﬁ c). 
 Migration and invasion assays 
 Tumor cells (100,000 cells/well) were cultured 
using a 24-well E-plates Transwell with 8.0-μm pore 
polycarbonate membrane inserts (Costar, Corning Inc.) in 
RPMI containing 1% exosome-depleted FBS. For invasion 
assays, Matrigel was applied to the upper surface of the 
membranes of Transwells (BD Biosciences). Similarly, 
T47D mock cells were incubated with CXCR4 or mock 
breast tumor-derived exosomes. Migration and invasion 
rates were analyzed by CellTiter-Glo ® Luminiscent Cell 
Viability Assay (Promega Corp.) and ﬂ uorescence reader 
(Tecan Inﬁ nite 200 Pro). 
 Flow cytometry 
 Activity of ALDH was analyzed in cell lines using 
ALDEFLUOR assay (Stemcell Technologies) following 
the manufacturer’s instructions. FACS analysis of surface 
antigens CD44 and CD49f was performed to identiﬁ ed 
subpopulation of breast cancer stem cells [ 25 ] (details 
in Supplementary Material). Data were acquired in a 
MACSQuant Analyzer using the MACSQuantify™ 
Software version 2.5 (Miltenyi Biotec S.L.). Results 
reported as percentage of positive cells for ALDH and as 
mean ﬂ uorescence intensity (MFI) for CD44 and CD49f. 
 Animals and tumor xenografts 
 All experimental procedures were performed in 
accordance with the Spanish Government guidelines for 
the care and use of laboratory animals and were approved 
by the Hospital Universitario Puerta de Hierro Animal 
Care and Use Committee (CEBA). 
 Five-week-old female athymic nude mice (Hsd: 
Athymic Nude-Foxn1nu mice, Harlan Laboratories, 
Barcelona, Spain) were used for xenograft experiments. 
For the analysis of tumorigenesis, we injected 1 × 10 6
T47D-CXCR4 or T47D mock cells and 1 × 10 6 MDA-MB-
231-CXCR4 or MDA-MB-231 mock cells suspended in a 
20% Matrigel matrix (Matrigel™ Basement Membrane 
Matrix, BD Biosciences) into the second left mammary 
fat pad of each mouse. Tumors were measured three 
times per week using precision calipers. Tumor volume 
was calculated as width 2 × length × 0.52. To analyze the 
role of exosomes in tumor growth and metastasis, 1 × 10 6
MDA-MB-231 FLuc cells were injected into the mammary 
fat pad. For exosome treatment, 20 μg of CXCR4 or 
mock exosome (in a total volume of 200 μL of PBS) was 
injected into the tail vein three times a week for 5 weeks. 
Tumors were also measured three times per week. As 
mice injected with T47D mock cells did not develop 
tumors, mice were pre-treated with T47D-CXCR4-derived 
exosomes for three weeks before inoculation with T47D 
cells. After exosome pre-treatment, mice received the 
orthotopic inoculation of 1 × 10 6 T47D mock cells. From 
this point, T47D-CXCR4-derived exosomes and T47D-
mock-derived exosomes were injected for three weeks. 
 At the end of experiments, mice were euthanized 
and their tumors and organs were excised for subsequent 
examination. The presence of metastatic cells in lymph 
nodes was assessed by ﬂ uorescence detection using a 
TCS SP5 confocal microscope (Leica Microsystems) 
and analyzed by Leica Application Suite 2.02. Moreover, 
analysis of tumor growth and metastasis in mice with tumor 
generated by MDA-MB-231 FLuc was performed by  in vivo
and  ex vivo BLI. For details, see Supplementary Material. 
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 Immunohistochemistry analysis 
 Immunohistochemistry and mitotic rate analysis 
of mice tissue sections were performed as described 
elsewhere [ 26 ]. 
 Patient samples, clinico-pathological parameters 
and follow-up 
 A series of 201 plasma samples from patients with 
breast cancer were provided by Biobank HUPH-M. The 
study was approved by the Research Ethics Board of the 
Hospital Universitario Puerta de Hierro-Majadahonda. 
The parameters obtained from the medical records of 
all the patients, prospective follow-up and therapies are 
mentioned in Supplementary Material. OS and DFS, 
deﬁ ned as the period from time of diagnosis until death 
and the interval between diagnosis and ﬁ rst recurrence, 
respectively, were the study end-points. Exosome mRNA 
was detected in the plasma of 173 patients. The remaining 
cases were eliminated from the study. 
 Statistical analysis 
 Comparisons between gene expression levels  in vitro 
and functional effects on cancer cells were contrasted using 
the Student’s  t -test after evaluation of equality of variance 
with Levene’s test. Results obtained from experiments 
requiring cultured cell lines and mice were expressed 
as mean ± standard deviation of at least three separate 
experiments. For survival study patients, we used optimal 
criterion value corresponding with the Youden’s index 
to divide mRNA data of evaluated genes in high or low 
levels to discriminate between two populations (presence 
or absence of ﬁ rst relapse and death for SLE and OS, 
respectively). The relationship between the cumulative 
probability of OS and PFS, as well as analyzed predictors, 
was calculated by the Kaplan-Meier method, while 
signiﬁ cant differences between curves were evaluated 
with Mantel’s log-rank test. To identify factors that might 
be of independent signiﬁ cance in inﬂ uencing OS and DFS, 
the Cox proportional risk regression model was used. The 
clinical-pathological parameters were contrasted with the 
presence of evaluated mRNA by the χ 2 test. In Box Plot 
representations, data were standardized by log 10 . 
 Two-tailed  p values ≤0.05 were considered 
signiﬁ cant.  P -values showed in ﬁ gures are represented as: 
*,  p ≤ 0.05; **,  p ≤ 0.01; and ***,  p ≤ 0.005. The mean 
and standard deviation (SD) were calculated by using 
Prism V (Graphpad Software), and error bars represent 
the SD. Statistical analysis used the SPSS, version 14.0. 
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